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Targeted therapies promise to revolu-
tionize the care of cancer patients. The
most dramatic examples of the potential
power of this approach come from suc-
cesses with the small molecule imatinib
mesylate, also known as Gleevec or
STI571. Imatinib effectively inhibits the
aberrant signaling properties and malig-
nant consequences of oncogenic BCR-
ABL, KIT, and PDGFRA in patients with
chronic myelogenous leukemia (CML)
(Druker et al., 1996, 2001b), gastroin-
testinal stromal tumor (GIST) (Demetri et
al., 2002; Tuveson et al., 2001), and
hypereosinophilic syndrome (HES)
(Cools et al., 2003a), respectively.
Treatment with imatinib as a single
agent, however, also reveals an inherent
weakness of monotherapy—the emer-
gence of tumor resistance (Cools et al.,
2003a; Demetri et al., 2002; Druker et al.,
2001a). Almost invariably in each of
these malignancies, disease resistance
develops after differing degrees of initial
response and latency. Recent articles by
Cools et al. (2003b [this issue of Cancer
Cell]), La Rosée et al. (2002), and Huron
et al. (2003) describe preclinical studies
of structurally distinct tyrosine kinase
inhibitors against imatinib-resistant
PDGFRA and BCR-ABL alleles, and
suggest that tumor resistance to target-
ed therapeutics is not insurmountable. In
the context of these studies, we briefly
discuss potential mechanisms that dic-
tate responsiveness and resistance to
therapies directed against oncogenes
and consider the challenges that lie
ahead.
First, why does targeted therapy
work? To date, none of the targeted ther-
apeutics in use, or in development, is
specific for a mutated state of a protein.
Rather, they additionally inhibit wild-type
functions of one or more cellular pro-
teins. Thus, cancer cells appear to
demonstrate a particular sensitivity to
these agents. Indeed, central to the suc-
cess of imatinib is the vulnerability of
tumor cells to the disruption of dominant
oncogenic pathways, a phenomenon
aptly referred to as “oncogene
dependence” or “oncogene addiction”
(Weinstein, 2002). Oncogene depen-
dence is hypothesized to result from the
subversion and reorganization of normal
cellular signaling networks by an intro-
duced dominant oncogene; removal or
modulation of the oncogene leads to
alterations in the aberrant signaling net-
work that are detrimental to cell prolifera-
tion and/or survival (Fan et al., 2002;
Weinstein, 2002). The protooncogenic
counterparts do not form aberrant sig-
naling networks, which may partially
explain the therapeutic index of targeted
therapeutics.
Preclinical evidence supporting this
model of oncogene dependence has
been provided by both cell culture exper-
iments and transgenic mouse tumor
models. Druker and colleagues demon-
strated in their landmark study that IL-3-
dependent, imatinib-resistant M07
human megakaryocytic cells and 32D
murine myeloid cells subsequently
became IL-3 independent and imatinib
sensitive following transfection with
BCR-ABL (Druker et al., 1996).
Interestingly, M07 and 32D cells that
were transformed with BCR-ABL and
cultured in the absence of IL-3 were still
sensitive to the apoptotic effects of ima-
tinib even after the media were supple-
mented with IL-3, suggesting a new and
unexplained requirement of the trans-
fected cells for the introduced oncogene.
An elegant series of experiments by
Weiss and colleagues extended these
observations to immortalized NIH 3T3
fibroblasts transfected with v-erbB or v-
src. Subsequent inhibition of these onco-
genes with allele-specific chemical
inhibitors did not merely revert the cells
from a fully transformed to an immortal-
ized state, but rather led to the arrest of
cellular proliferation (Fan et al., 2002).
Furthermore, this arrested phenotype
was at least partially attributable to
diminished Raf kinase signaling and
cyclin D1 levels, known downstream
mediators of v-erbB2 and v-src.
Additional insight has come from
inducible transgenic mouse models of
melanoma (Chin et al., 1999), leukemia
(Felsher and Bishop, 1999; Huettner et
al., 2000), breast cancer (Moody et al.,
2002), and lung cancer (Fisher et al.,
2001) have provided powerful systems to
demonstrate the requirement of “tumor
maintenance” on the initiating onco-
genes H-rasG12V, c-myc, BCR-ABL
erbB2, and K-rasG12D, respectively. In
many of these systems, when expres-
sion of the relevant oncogene was sub-
sequently turned off, the malignant
phenotype regressed rapidly, accompa-
nied by widespread apoptosis and
growth arrest. Of particular relevance to
targeted therapeutics in human malig-
nancy, these initiating oncogenes were
similarly required for tumor maintenance
in mouse models that additionally har-
bored multiple tumor suppressor gene
mutations (Chin et al., 1999; Fisher et al.,
2001).
Clinically, oncogene dependence
has been observed in both biochemical
and genetic analyses in patients under-
going treatment with imatinib. A direct
correlation has been demonstrated
between disease responsiveness and
the interruption of downstream Bcr-Abl
biochemical pathways, such as Crkl
phosphorylation (Gorre et al., 2001).
Interestingly, investigations into the
nature of relapsed and resistant disease
in CML patients treated with imatinib led
to the discovery of mutations in the BCR-
ABL locus, substantiating the essential
role of this oncogene in maintaining the
diseased state (Gorre et al., 2001).
So, why does targeted therapy fail?
Several mechanisms of resistance to
imatinib in CML patients have been
described (Gorre et al., 2001; Hochhaus
et al., 2002; Shah et al., 2002). The
majority of CML patients with resistance
to imatinib have a clonal expansion of
leukemic cells harboring novel mutant
BCR-ABL alleles. These mutations con-
fer reduced sensitivity to inhibition by
imatinib and segregate either as direct
contact site mutants within the kinase
domain or as allosteric modifiers of the
preferred conformational state of Bcr-Abl
for imatinib binding. BCR-ABL gene
amplification provides yet another mech-
anism of resistance seen in patients, and
results in sufficient unbound, active
kinase to maintain the neoplastic state.
Although clinical resistance to imatinib
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Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy.
The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emer-
gence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.
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usually develops after an initial
response, mutation and amplification of
the BCR-ABL locus can be detected in
the leukemic cells of some patients even
prior to the initiation of therapy (Shah et
al., 2002). The preponderance of muta-
tions at the BCR-ABL locus in patients
with CML is currently unexplained, and
postulated mechanisms include an
increased mutational rate in progenitor
cells and neomorphic properties of
mutant Bcr-Abl proteins (Shah et al.,
2002). Mutations or amplification of the
dependent oncogene that directly
impede the bimolecular interaction
between a critical fraction of the onco-
protein and the targeted therapeutic at
clinically relevant drug concentrations
may be best characterized as forms of
“target resistance.”
Interestingly, in some imatinib-resis-
tant CML patients, neither mutation nor
amplification of the BCR-ABL locus can
be detected, indicating that other forms
of resistance must also occur in vivo
(Gorre et al., 2001; Shah et al., 2002).
Indeed, preclinical data have suggested
the presence of at least two additional
mechanisms for the lack of response to
targeted therapeutics. First, “pharmaco-
kinetic resistance” to targeted therapeu-
tics might occur by a variety of
mechanisms that decrease drug delivery
to or increase drug efflux by the cancer
cells. For example, α-1 acidic glycopro-
tein has been shown to bind imatinib and
reduce serum drug levels in       a murine
CML xenograft model (Gambacorti-
Passerini et al., 2000). Although there
have been as yet no reports of such
resistance in patients treated with ima-
tinib, careful pharmacokinetic studies in
serum and target tissue are required in
patients who do not respond to imatinib
and who do not have target resistance.
Finally, in patients with “biological resis-
tance,” the cancer cells are no longer
dependent on the targeted oncogene.
Biological resistance may occur due to
the presence of additional dominant
oncogenes in the tumor cells that are not
inhibited by the targeted therapeutic
(secondary oncogene dependence), or
may be an innate property of some can-
cer stem cells that make them impervi-
ous to disruption of targeted oncogenic
pathways. Evidence for the latter possi-
bility has been found in the form of
pluripotent, quiescent CML cells that
have been isolated from patients and are
capable of sustained survival during
incubation with imatinib in vitro (Graham
et al., 2002).
Given the ever increasing number of
patients with a variety of malignancies
that are demonstrating resistance to
imatinib following initial response, the
articles by Cools et al. (2003b), La
Rosée et al. (2002), and Huron et al.
(2003) are especially timely. La Rosée et
al. showed that a novel pyrido[2,3-
d]pyrimidine derivative (PD180970),
originally developed as a Src kinase
inhibitor, had potent activity in cell culture
against a number of BCR-ABL mutants
commonly found in imatinib-resistant
patients. A structurally related compound
(PD166326) that effectively inhibits sig-
naling downstream of another imatinib-
resistant allele, BCR-ABLE255K, was
recently described by Huron et al.
(2003). As the backdrop to their work
described in this issue, Gilliland and col-
leagues recently demonstrated that the
development of hypereosinophilic syn-
drome (HES), and its sensitivity to ima-
tinib, appear to result from an
intrachromosomal deletion that creates a
novel fusion tyrosine kinase, FIP1L1-
PDGFRA, in a majority of patients (Cools
et al., 2003a). Moreover, an HES patient
that developed target resistance to ima-
tinib was found to harbor a mutant
FIP1L1-PDGFRAT674I allele, and structur-
al considerations predicted that this
mutation would interfere with imatinib
binding to the PDGFRA kinase domain.
In the current issue, Cools et al. now
show that PKC412, a staurosporine
derivative with widespread activity
against tyrosine kinases, can effectively
inhibit signaling by the PDGFRAT674I
kinase in cell culture and prevent
PDGFRAT674I-induced myeloproliferative
disease in a mouse transplant model.
This represents the first in vivo demon-
stration of overcoming target resistance
with a second targeted therapeutic.
Collectively, these results are significant
because they show that, in principle, tar-
get resistance can be overcome with
alternative, structurally distinct agents
directed against the same enzymatic
activity in an oncoprotein. Importantly,
each of these alternative inhibitors is
effective for specific sets of mutant alle-
les. For example, PKC412 does not
inhibit the PDGFRAN659D allele, and nei-
ther PD166326 nor PD180970 inhibits
one of the most common imatinib-resis-
tant alleles in CML, BCR-ABLT315I.
Indeed, the non-crossresistant nature of
these agents is thought to reside in their
predilection for binding different confor-
mational states of the kinase domain.
Thus, these studies also underscore the
importance of understanding not only
the mechanisms of emerging disease
resistance, but also the detailed mecha-
nisms of drug sensitivity. Ultimately, the
clinical utility of such agents will depend
not only on their spectra of activities
against common mutant alleles, but also
on their respective bioavailability and
toxicity profiles. As PKC412 is currently
undergoing evaluation in phase 1/2 tri-
als, the results of Cools et al. should
prompt the rapid approval of clinical pro-
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Table 1. Mechanisms of resistance to Imatinib
Type Oncogene 2° Oncogene Locus In vivo Alternative
dependence dependence therapy
Target
Mutations + - Bcr-Abl; PDGFRA + PKC412, PD166326, PD180970
Amplification + - Bcr-Abl + Geldanamycin
Pharmacokinetic
Extracellular + - α-1 glycoprotein - ND
Cellular + - P-glycoprotein - ND
Biological
Alternate pathway - + ND - ND 
Innate ± - CML stem cell + ND
In vivo, observed in vivo or in patient-derived material; ND, not determined.
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tocols to evaluate efficacy in patients
with imatinib-resistant HES, and perhaps
other malignancies, who could potential-
ly benefit.
Clinical experience with imatinib has
provided invaluable insight into the
processes necessary to sustain malig-
nancy in vivo, and prompts consideration
of the best way forward. Initially, wherev-
er possible, candidate oncogene targets
must be identified for each malignancy
by establishing if oncogene dependency
and the accompanying aberrant signal-
ing network are operant in that cancer.
Ironically, the malignancies we know the
least about in this regard are also the
most common causes of adult death
from cancer, including lung, colorectal,
breast, and prostate, although onco-
genic alleles of K-ras and BRAF are
potential candidates in some, and over-
expressed erbB2 has been targeted with
the Herceptin monoclonal antibody in
breast cancer (Vogel et al., 2002). Small
molecule inhibitors, RNA interference
(Brummelkamp et al., 2002), and pro-
teomic techniques are amongst the
methodologies that can be used to iden-
tify and characterize potential dominant
oncogenes.
Resistance to molecular therapeutics
that target oncogenes will likely occur by
one or more mechanisms in most, if not
all, patients (Table 1). By extension of the
work discussed here (Cools et al., 2003a;
Huron et al., 2003; La Rosée et al.,
2002), target resistance will be common
in advanced malignancies and several
novel agents will be required to combat
each oncoprotein. For example, some
CML patients who relapsed after
response to imatinib had at least four
unique mutant BCR-ABL alleles identi-
fied in their leukemic cells, emphasizing
the polyclonal potential of target resis-
tance (Shah et al., 2002). Combination
therapy with multiple targeted agents
may lead to faster responses and more
durable remissions. Additional methods
to attack the primary target have been
proposed, such as Geldanamycin, which
diminishes Bcr-Abl protein levels by
inhibiting the function of the molecular
chaperone and heat shock protein,
Hsp90 (Gorre et al., 2002). Importantly,
Geldanamycin is equally effective against
native and mutant Bcr-Abl protein and
may be particularly useful in combination
with kinase inhibitors in cases of BCR-
ABL amplification. Pharmacokinetic
resistance to imatinib has not been
demonstrated thus far in patients, but
may become more problematic due to
drug interactions as combinations of tar-
geted therapeutics are assessed in
patients. The ability to assess drug levels
and biochemical pathways in small tumor
samples is critical to properly evaluate
novel therapeutics and will require sensi-
tive proteomic, genomic, and pharmaco-
logical approaches. Biological resistance
that is due to secondary oncogene
dependence may be directly treated with
the appropriate targeted agents.
However, biological resistance due to the
innate features of primitive progenitor
cancer cells, or “cancer stem cells,” (Reya
et al., 2001) may pose the most difficult
challenge of all. Cancer stem cells may
not be as responsive as progeny cells to
the inhibition of dominant oncogenic
pathways, and a deeper understanding of
the properties of these cells is therefore
critical. For example, the inability of ima-
tinib to kill multipotential CML precursor
cells in vitro (Graham et al., 2002) sug-
gests that monotherapy will only be effec-
tive as a continuous therapy and, then,
only until resistant disease appears.
Indeed, curative intent by targeted agents
may not be realized until the advent of
specific strategies to combat the cancer
stem cell.
The unfolding story of imatinib is
reminiscent of experience over the past
two decades with the development of
effective anti-retroviral therapies for the
human immunodeficiency virus.
Resistance to reverse transcriptase
monotherapy was addressed first with
alternative individual drugs and then with
combinations of agents that target two or
more pathways. Reasonable combina-
tion therapeutic approaches would target
additional pathways in cancer cells
(Hoover et al., 2002; Nakajima et al.,
2003; Yu et al., 2002), as well as non-
cell-autonomous characteristics of the
tumor microenvironment. The role of
conventional chemotherapy and radia-
tion therapy in combination with targeted
therapeutics is being evaluated; howev-
er, in principle, these highly mutagenic
modalities may inadvertently spawn
increased resistance to targeted agents.
Future success will depend upon the
availability of multiple versions of target-
ed agents that modulate the function of
dominant oncogenes and other impor-
tant cancer genes, rapid methods to
determine disease responsiveness and
resistance, and willingness within the
pharmaceutical industry to conduct col-
laborative clinical trials using combina-
tions of novel targeted therapies. If these
goals are pursued cooperatively, this
new era of molecular oncology may
indeed fulfill its long-awaited promise.
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Ovarian cancer cells accumulate genetic
changes that allow them to evade
chemotherapeutic drugs and become
increasingly dangerous. In view of the
high mortality rates associated with ovar-
ian cancer, a better understanding of the
molecular mechanisms underlying tumor
progression in the disease could reveal
novel pathways of high clinical rele-
vance. A key feature of ovarian cancer is
its sensitivity to platinum salts such as
Cisplatin (CDDP) and Carboplatin, two
drugs that have been the mainstay of
therapy for decades. Unfortunately, ovar-
ian cancer cells, with their unstable
genomes, are initially sensitive to this
class of drugs, but the cells invariably
become resistant.
In a recent study, Taniguchi et al.
(2003) describe a model for ovarian
tumor progression in which the initial
methylation of FANCF, a gene associat-
ed with Fanconi anemia, is followed by
FANCF demethylation and CDDP resis-
tance. FANCF is one of seven recently
cloned Fanconi anemia genes whose
protein products were found to interact
with proteins involved in DNA repair
pathways, including BRCA1, RAD51,
ATM, and NBS1 (D’Andrea and Grompe,
2003). Five of the FANC gene products
(FANCA, FANCC, FANCE, FANCF, and
FANCG) are subunits of a nuclear com-
plex (FA complex) that is required for the
monoubiquitination of the downstream
FANCD2 protein (Figure 1A). The sev-
enth gene, FANCD1, was recently shown
to be identical to BRCA2 (Howlett et al.,
2002). Defects in the Fanconi-anemia-
BRCA (FA-BRCA) pathway are associat-
ed with genomic instability and
increased sensitivity to DNA-damaging
agents such as ionizing radiation (IR),
mitomycin C (MMC), and CDDP. In
response to ionizing radiation-mediated
double-strand breaks, ATM phosphory-
lates the NBS1 protein. Phosphorylation
of NBS1 is required for FANCD2 phos-
phorylation at serine 222, leading to acti-
vation of an S phase checkpoint. In
response to DNA damage, the FA com-
plex mediates ubiquitination of FANCD2
at lysine 561. Activated FANCD2 is
translocated to chromatin and DNA
repair foci, which contain the BRCA1
protein and BRCA2/FANCD1 protein
complex. BRCA2/FANCD1 binds to
RAD51 and to DNA, promoting a DNA
repair response. The ubiquinated
FANCD2 also colocalizes with NBS-
MRE11-RAD50 complex in DNA dam-
age nuclear foci. Germline mutation of
several genes in the pathway result in
impaired response to DNA damage and
increased cancer susceptibility.
FANCD2 exists as two isoforms in
normal cells, nonubiquitinated FANCD2-
S and monoubiquitinated FANCD2-L.
Inducible expression of monoubiquitinat-
ed FANCD2 in response to DNA damage
requires an intact FA-BRCA pathway.
Taniguchi et al.(2003) screened 25 ovar-
ian cancer cell lines with varying sensi-
tivities to CDDP and found two cell lines,
2008 and TOV-21G, without the
FANCD2-L isoform. Compared to other
ovarian cancer cell lines, both 2008 and
TOV-21G are hypersensitive to CDDP
with half maximal inhibitory concentra-
tion (IC50) less than 1.0 µm of CDDP.
TOV-21G cells were retrovirally trans-
duced with various FANC cDNAs
(FANCA, FANCC, FANCE, FANCF,
FANCG) in an attempt to correct any
FANCF methylation contributes to chemoselectivity in ovarian
cancer
A new model of ovarian cancer tumor progression implicates aberrant FANCF promoter methylation that is associated with
gene silencing and disruption of the Fanconi-anemia-BRCA pathway. Disruption of the pathway occurs de novo in ovarian
cancers and may contribute to selective sensitivity to platinum salts.
